New Preclinical Data for Calcipotriol/betamethasone dipropionate(0,005%/0,05%)
Foam Presented at American Academy of Dermatology Congress
MARKHAM, ON--(March 7, 2016) - Data presented in a Late Breaking Science session at the 74th Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C. demonstrated that calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) foam formulation is a stable supersaturated solution of the active ingredients.footnote 11 The data presented at AAD showed that no calcipotriol or betamethasone dipropionate crystals were identified in the foam spray following application and for up to 18 hours.
"We are extremely pleased with the results of this preclinical study, which continue to build our base of evidence to support the efficacy for our product and illustrate why this treatment can make a difference to people living with psoriasis vulgaris," said Gitte Aabo, President and CEO of LEO Pharma. "The data presented at AAD highlight the supersaturation of the product and provide further of evidence of how the product can help patients living with psoriasis vulgaris."
"Supersaturation is important for a topical treatment from a dermatological perspective, as it has been shown to improve how effectively a medicine can penetrate the skin," said Dr. Richard Warren, Senior Lecturer and study author. The safety and efficacy of calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) foam are still under investigation. Market authorisation in Canada has not yet been obtained.
Psoriasis is a chronic, inflammatory skin disease, which is frequently accompanied by multiple physical and/or psychological comorbidities, such as metabolic syndrome and psoriatic arthritis.footnote 22
Psoriasis is estimated to affect about 2-4% of the population in western countries.footnote 33 80% of patients are affected by psoriasis vulgaris – the most common type of psoriasis.footnote 44
Topical treatments are first-line therapies for the majority of patients suffering from psoriasis.footnote 55
About LEO Pharma A/S
LEO Pharma helps people achieve health skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.
- Warren R, et al. Supersaturation of calcipotriene and betamethasone dipropionate – facilitating the improved clinical efficacy of the fixed combination spray foam LEO90100 (calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD)) as compared to other formulations of Cal/BD (abstract)
- Taraska V, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) exhibits no impact on the HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris: a multicenter, single-arm, Phase II, 4-week MUSE study. Presented at the Skin Disease Education Foundation’s 15th Annual Las Vegas Dermatology Seminar & the 11th Annual SDEF Psoriasis Forum, October 30-November 1, 2014
- Parisi R, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. The Society for Investigative Dermatology. J Invest Dermatol 2013;133(2):377-85
- Reich K, et al. Efficacy of a fixed combination of with calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicentre, randomized, controlled, prospective study. Journal of European Academy of Dermatology Venereology 2014: October (epub ahead of print) DOI: 10.1111/jdv.12774
- Men. ter A, Korman NJ, Elmets CA et alGuidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the manage-ment and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60: 643–659